Symptoms Burden as a Clinical Outcomes Assessment in Heart Failure Patients With Atrial Fibrillation
Measurement of symptoms burden throughout clinical trial follow-up is feasible in AF/HF and should be useful for evaluating patient-centered outcomes in AF prevention trials. (Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure [GENETIC-AF]; NCT01970501).
Authors
- Benjamin Adam Steinberg (ORCID: https://orcid.org/0000-0002-4729-7820)
- Wendy S. Tzou (ORCID: https://orcid.org/0000-0002-8514-1165)
- Jonathan Paul Piccini (ORCID: https://orcid.org/0000-0003-0772-2404)
- Michael R. Bristow (ORCID: https://orcid.org/0000-0002-8860-4698)
- David L. DeMets (ORCID: https://orcid.org/0000-0003-3348-8754)
- Ian A. Carroll (ORCID: https://orcid.org/0000-0003-2071-5479)
- Jennifer C. Richards
Institutions
- Duke University (US)
- University of Utah (US)
- ARCA Biopharma (United States) (US)
- Duke Medical Center (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- JACC Heart Failure
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1016/j.jchf.2024.08.023
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- ARCA Biopharma